US Health & Fitness
Regulatory pressure is mounting on Amgen’s inflammatory disorder drug, Tavneos, with the European Medicines Agency recommending revocation of the product’s approval in its territory.…
The road to interoperability is long, but not impossible. In healthcare, this decades-long effort to…
Healthcare data is just messy. That’s the simplest way to put it. It doesn’t live…
On February 23, the FDA did something the rare disease community has spent a decade…
Healthcare leaders spend a lot of time talking about how they’re improving the system —…
Healthcare costs in the U.S. are growing faster than inflation, and the U.S. spends significantly…
Rocket Pharmaceuticals sold its rare disease pediatric priority review voucher for $180 million, cash that…
